1751 RIVER RUN, FORT WORTH, TX
Actuate Therapeutics Enters $100 Million At The Market Issuance Agreement
Other Events
Announces Pricing of $15.0 Million Public Offering of Common Stock
News, Securities Holder Rights or Indentures, Material Contracts
Transcript of Key Opinion Leader Event
Elraglusib Phase 2 Data Shows Promise in Pancreatic Cancer at ASCO 2025
Shareholder votes
Q3
Q1
FY 2024
Q2
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
S-1
Additional Proxy Materials
Definitive Proxy Statement
Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Free Writing Prospectus
Amended Form D Notice of Exempt Offering of Securities